Print this page
-
A Phase I Study of Autophagy Inhibition with Hydroxychloroquine and Oral Decitabine with Venetoclax after Hypomethylating Agent and Venetoclax Failure in Acute Myeloid Leukemia.
Protocol: 022601Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms.
Protocol: 022608Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Protocol: 022602Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms.
Protocol: 022608Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast